Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
View Top Employees from Aquestive TherapeuticsWebsite | https://www.aquestive.com |
Ticker | NASDAQ:AQST |
Employees | 131 (131 on RocketReach) |
Founded | 2000 |
Address | 30 Technology Drive, Warren, New Jersey 07059, US |
Phone | (908) 941-1900 |
Technologies |
JavaScript,
HTML,
PHP
+54 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Pharmaceutical, Health Care |
Looking for a particular Aquestive Therapeutics employee's phone or email?
Cathy Sands is the Chief Medical Officer of Aquestive Therapeutics.
131 people are employed at Aquestive Therapeutics.
Aquestive Therapeutics is based in Warren, New Jersey.